Total submissions: 21
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000443008 | SCV000521309 | pathogenic | not provided | 2023-03-24 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25552650, 29302074, 31130284, 32371413, 33644862, 32895917, 32979048, 31345219, 27535533, 28708303) |
Groupe Hospitalier Pitie Salpetriere, |
RCV000223666 | SCV000586778 | likely pathogenic | Hereditary spastic paraplegia 52 | 2017-01-06 | criteria provided, single submitter | clinical testing | Intellectual disability, moderate; acquired microcephaly (-4SD); hypotonia; epilepsy (starting at 2 months old) |
Genetic Services Laboratory, |
RCV000443008 | SCV000593255 | pathogenic | not provided | 2021-01-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000525844 | SCV000629434 | pathogenic | Spastic paraplegia | 2024-10-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg97*) in the AP4S1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AP4S1 are known to be pathogenic (PMID: 21620353, 25552650, 27444738). This variant is present in population databases (rs200440467, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (PMID: 25552650). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 234924). For these reasons, this variant has been classified as Pathogenic. |
Eurofins Ntd Llc |
RCV000443008 | SCV000859814 | pathogenic | not provided | 2018-02-16 | criteria provided, single submitter | clinical testing | |
Centre for Mendelian Genomics, |
RCV000223666 | SCV001368406 | pathogenic | Hereditary spastic paraplegia 52 | 2019-04-02 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS1,PM2. |
Institute for Genomic Medicine |
RCV000223666 | SCV001423591 | pathogenic | Hereditary spastic paraplegia 52 | 2019-02-22 | criteria provided, single submitter | clinical testing | [ACMG/AMP: PVS1, PM2, PM3, PP1] This alteration is a null variant in a gene where LOF is a known mechanism of disease [PVS1], is absent from or rarely observed in large-scale population databases [PM2], is detected in trans with a known pathogenic variant [PM3], has been shown to cosegregate with disease in multiple affected family members [PP1]. |
Diagnostic Laboratory, |
RCV001260893 | SCV001437993 | pathogenic | Intellectual disability | 2020-09-10 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV000443008 | SCV001447536 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Kasturba Medical College, |
RCV000223666 | SCV001478364 | pathogenic | Hereditary spastic paraplegia 52 | 2019-12-19 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000223666 | SCV002021412 | pathogenic | Hereditary spastic paraplegia 52 | 2022-07-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000223666 | SCV002792570 | pathogenic | Hereditary spastic paraplegia 52 | 2022-02-10 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000223666 | SCV004175975 | pathogenic | Hereditary spastic paraplegia 52 | 2023-11-09 | criteria provided, single submitter | clinical testing | Criteria applied: PVS1,PS4_MOD,PM3,PM2_SUP |
Genomic Medicine Center of Excellence, |
RCV000223666 | SCV004806903 | pathogenic | Hereditary spastic paraplegia 52 | 2024-03-26 | criteria provided, single submitter | clinical testing | |
Institute of Immunology and Genetics Kaiserslautern | RCV000223666 | SCV005077715 | pathogenic | Hereditary spastic paraplegia 52 | 2024-05-22 | criteria provided, single submitter | clinical testing | ACMG Criteria: PVS1, PS3, PM3, PM2_P, PP5; Variant was found in homozygous state in both the patient and the patient's brother (also affected). |
Juno Genomics, |
RCV000223666 | SCV005416591 | pathogenic | Hereditary spastic paraplegia 52 | criteria provided, single submitter | clinical testing | PVS1+PM2_Supporting+PM3 | |
Rady Children's Institute for Genomic Medicine, |
RCV000223666 | SCV005900680 | pathogenic | Hereditary spastic paraplegia 52 | 2023-12-23 | criteria provided, single submitter | clinical testing | This nonsense variant found in exon 4 of 6 is predicted to result in loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. Loss-of-function variation in AP4S1 is an established mechanism of disease (PMID: 21620353, 25552650). This variant has been previously reported as a compound heterozygous and homozygous change in individuals with spastic paraplegia (PMID: 25552650, 28708303, 31130284, 32979048, 32371413). The c.289C>T (p.Arg97Ter) variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.01% (31/282750). Analysis of the parental samples showed the mother is heterozygous and the father is heterozygous for this variant. Based on the available evidence, c.289C>T (p.Arg97Ter) is classified as Pathogenic. |
OMIM | RCV000223666 | SCV000280013 | pathogenic | Hereditary spastic paraplegia 52 | 2018-06-21 | no assertion criteria provided | literature only | |
Genome |
RCV001249232 | SCV001423167 | not provided | AP4S1-related disorder | no assertion provided | phenotyping only | Variant interpretted as Pathogenic and reported on 04-16-2018 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. | |
Yale Center for Mendelian Genomics, |
RCV000525844 | SCV002106897 | likely pathogenic | Spastic paraplegia | 2020-10-01 | no assertion criteria provided | literature only | |
Dr. |
RCV000223666 | SCV005061407 | pathogenic | Hereditary spastic paraplegia 52 | no assertion criteria provided | clinical testing |